HIV InfectionNCT00247091
Impact of HIV on Measles and Measles Immunisation
An observational study of HIV Infection and Measles, run by Johns Hopkins Bloomberg School of Public Health at 1 site in Zambia.
Trial summary
We conducted a longitudinal study to assess the immunogenicity of standard-titer measles vaccine in HIV-infected and uninfected Zambian children. The study hypothesis was that HIV-infected children would have higher rates of primary and secondary measles vaccine failure compared to uninfected children, contributing to… Read more about this study
- Who is it for?
- Ages 2 to 15 monthsHealthy volunteers can take part
- Conditions the study is for
- HIV Infection, Measles, Children
- What is being tested?
- standard-titer measles vaccine
- Type of treatment
- Vaccines
- How many people
- 700 participants
- Where
- 1 siteZambia
- Study dates
- May 2000to Sep 2004
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 to 15 months
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- children aged 2 to 8 months presenting for well-child care
- reside within 10 miles of the study clinic
- parents or caretakers provide signed informed consent
Who cannot join
- -children with severe illness
Trial locations and contacts
1 site in 1 country.
About this study
We conducted a longitudinal study to assess the immunogenicity of standard-titer measles vaccine in HIV-infected and uninfected Zambian children. The study hypothesis was that HIV-infected children would have higher rates of primary and secondary measles vaccine failure compared to uninfected children, contributing to decreased levels of population immunity to measles and facilitating measles virus transmission in regions of high HIV prevalence.
Read the detailed description
Despite great progress in measles control in sub-Saharan Africa, measles remains a significant cause of morbidity and mortality in young children. In regions of high HIV prevalence, measles virus transmission may be sustained despite high immunization coverage rates if HIV-infected children are important transmitters of measles virus. Factors potentially contributing to enhanced measles virus transmission by HIV-infected children include an early decline in protective maternal antibody titers resulting in susceptibility to measles at a younger age, and high rates of primary and secondary measles vaccine failure. To evaluate the potential impact of the HIV-1 epidemic on immunity following measles vaccination, we conducted a longitudinal study to compare the primary vaccine failure rate and rate of antibody decline following administration of standard-titer measles vaccine at nine months of age to HIV-infected and HIV-uninfected Zambian children. Our results show that children born to HIV-infected women have lower levels of passively-acquired maternal antibodies to measles virus prior to the age of routine vaccination at 9 months, and HIV-infected children are particularly susceptible to measles in infancy. This finding supports the WHO recommendation to provide the first dose of measles vaccine to HIV-infected children at 6 months. Furthermore, HIV-infected children develop adequate primary antibody responses to measles vaccine in the months following vaccination but lose protective antibody titers by two to three years of age. Mitigating the potential impact of this decreased immunogenicity on the level of population immunity to measles virus was the high mortality rate observed among HIV-infected children. Improved access to antiretroviral therapy will likely improve the survival of HIV-infected children without enhancing protective immunity to measles virus, although this has yet to be investigated. We are working to incorporate our findings into a mathematical model to better understand the impact of the HIV-1 epidemic on measles control strategies and to investigate the immunologic mechanisms for impaired memory B cell responses in HIV-infected children.
- Conditions
- HIV Infection, Measles, Children
- Being tested
- standard-titer measles vaccine
- Keywords
- HIV, measles, measles vaccine, children, Zambia
- Medical subject headings
- HIV Infections, Measles
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
standard-titer measles vaccineBiological
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Nov 2005 (estimated)
- Study startMay 2000
- Study completionSep 2004
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HIV InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Defined population
- Time perspective
- Prospective
- Enrolment
- 700 participants
Sponsor and investigators
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Sponsor type
- University, hospital or other
- Collaborators
- Burroughs Wellcome, London School of Hygiene and Tropical Medicine, University of Zambia
- Investigators
- William J. Moss, MD, Principal investigator, Johns Hopkins University Bloomberg School of Public HealthFelicity Cutts, MD, Principal investigator, London School of Hygiene and Tropical MedicineFrancis Kasolo, MD, PhD, Principal investigator, University of Zambia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00247091
- Sponsor's protocol ID
- GR059114MA
- Status last verified
- Oct 2005
- First submitted
- 28 Oct 2005
- Last updated
- 1 Nov 2005
- Results posted
- No